Oberon Investments - EIS Subscription Update
RNS Number : 3091P
Oberon Investments Group PLC
17 February 2021
 

 

Baskerville Capital plc

('Baskerville', the 'Group' or the 'Company')

(To be renamed Oberon Investments Group plc)

('Oberon' or 'Oberon Investments')

 

EIS Subscription Update

 

Further to the announcement on 9 February 2021, the Company confirms that the balance of the subscription for £1.44m has now been received and 4,877,250 new ordinary shares issued.

 

The new ordinary shares will rank pari passu with the existing ordinary shares of the Company.  Following the issue of the new ordinary shares, the Company's issued share capital comprises 407,789,775 ordinary shares of 0.5p.

 

The above figure of 407,789,775 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

The directors of Baskerville Capital plc accept responsibility for this announcement.

 

FOR FURTHER INFORMATION PLEASE CONTACT:

 

Baskerville Capital plc

 

Simon McGivern

 

via Walbrook PR

AQSE Corporate Adviser and Broker

 

Novum Securities Limited

 

Richard Potts / Daphne Zhang / Lucy Bowden

020 7399 9400

 

 

Walbrook PR Ltd

Tom Cooper / Nick Rome

Tel: 020 7933 8780 or Oberon@walbrookpr.com

 

 

 

This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXUNVBRAKUUAAR ]]>